AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36410811 — intervention group
Group type: COMPARATOR
Intervention: Current practice of BCG vaccination
Number of subjects: 23
Study 33607823 — intervention group
Group type: EXPERIMENTAL
Intervention: External application of mirabilite and rhubarb combined with intrathoracic chemotherapy (cisplatin)
Number of subjects: 84
Study 34532785 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed intermittent epidural bolus (PIEB) 3 mL bolus every 60 min
Number of subjects: 58
Study 34532785 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural infusion (CEI) 3 mL/h
Number of subjects: 58
Study 32406659 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-supported fixed complete dentures
Number of subjects: 20
Study 32406659 — intervention group
Group type: COMPARATOR
Intervention: Conventional complete dentures
Number of subjects: 20
Study 33328057 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic decision support (rehydration calculator)
Number of subjects: 4975
Study 33328057 — intervention group
Group type: COMPARATOR
Intervention: Paper formatted WHO guidelines
Number of subjects: 4975
Study 36102447 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-switched laser
Number of subjects: 45
Study 36102447 — intervention group
Group type: COMPARATOR
Intervention: TCA peeling
Number of subjects: 45
Study 36102447 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 45
Study 32619057 — intervention group
Group type: EXPERIMENTAL
Intervention: Opalescence PF
Number of subjects: 0
Study 32619057 — intervention group
Group type: EXPERIMENTAL
Intervention: Opalescence Go
Number of subjects: 0
Study 32619057 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 32144189 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (four supervised sessions and home-based exercises)
Number of subjects: 235
Study 32144189 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 235
Study 32144189 — intervention group
Group type: COMPARATOR
Intervention: Control group (health education programme only)
Number of subjects: 235
Study 35120162 — intervention group
Group type: EXPERIMENTAL
Intervention: YOGA
Number of subjects: 60
Study 35120162 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 60
Study 33447861 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiomics-based nomogram using random forest
Number of subjects: 356
Study 33447861 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiomics-based nomogram using logistic regression
Number of subjects: 356
Study 33447861 — intervention group
Group type: EXPERIMENTAL
Intervention: MVI-positive (M2 and M1) patients
Number of subjects: 356
Study 33447861 — intervention group
Group type: EXPERIMENTAL
Intervention: MVI-negative (M0) patients
Number of subjects: 356
Study 33447861 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperatively predicted MVI by MVI nomogram using random forest
Number of subjects: 356
Study 34370166 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health educational intervention via WhatsApp messenger for 7 weeks on a daily schedule
Number of subjects: 38
Study 34370166 — intervention group
Group type: COMPARATOR
Intervention: Control group (no messages received)
Number of subjects: 38
Study 33300183 — intervention group
Group type: EXPERIMENTAL
Intervention: D/C/F/TAF 800/150/200/10 mg
Number of subjects: 1840
Study 33300183 — intervention group
Group type: EXPERIMENTAL
Intervention: D/C/F/TAF
Number of subjects: 1840
Study 32614482 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief self‐compassion intervention (two 2.5‐h sessions)
Number of subjects: 27
Study 32614482 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 27
Study 35691295 — intervention group
Group type: EXPERIMENTAL
Intervention: FINLAY-FR-1A vaccine (50 μg of recombinant dimeric receptor binding domain [RBD])
Number of subjects: 450
Study 35691295 — intervention group
Group type: EXPERIMENTAL
Intervention: FINLAY-FR-1A vaccine
Number of subjects: 450
Study 35691295 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vaccine excipient)
Number of subjects: 450
Study 33742194 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic exercise and diet
Number of subjects: 1401
Study 33742194 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1401
Study 33742194 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise alone
Number of subjects: 1401
Study 33742194 — intervention group
Group type: COMPARATOR
Intervention: Resistance exercise alone
Number of subjects: 1401
Study 33742194 — intervention group
Group type: COMPARATOR
Intervention: Resistance exercise with a healthy diet
Number of subjects: 1401
Study 32515703 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive counseling with a nutritional component and distant support via telephone (6 consultations over 3 months)
Number of subjects: 100
Study 32515703 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling by a health center physician
Number of subjects: 100
Study 34353299 — intervention group
Group type: EXPERIMENTAL
Intervention: KIND challenge (doing at least one act of kindness per week for four weeks)
Number of subjects: 0
Study 34353299 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study 33023516 — intervention group
Group type: EXPERIMENTAL
Intervention: Low risk scenario
Number of subjects: 942
Study 33023516 — intervention group
Group type: EXPERIMENTAL
Intervention: Average risk scenario
Number of subjects: 942
Study 33023516 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate risk scenario
Number of subjects: 942
Study 33023516 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk scenario
Number of subjects: 942
Study 33023516 — intervention group
Group type: EXPERIMENTAL
Intervention: General interest in breast cancer risk
Number of subjects: 942
Study 33023516 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education
Number of subjects: 942
Study 33023516 — intervention group
Group type: EXPERIMENTAL
Intervention: First degree family history of breast cancer
Number of subjects: 942
Study 33023516 — intervention group
Group type: EXPERIMENTAL
Intervention: General beliefs about medication
Number of subjects: 942
Study 35074603 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect Basophil Activation Test (BAT) for peanut extract, Ara h2, and Ara h6
Number of subjects: 74
Study 35074603 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect Basophil Activation Test (BAT) for Ara h2
Number of subjects: 74
Study 35074603 — intervention group
Group type: COMPARATOR
Intervention: Double-blind placebo-controlled food challenge (OFC)
Number of subjects: 74
Study 36403580 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol plus standard care
Number of subjects: 83
Study 36403580 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 83
Study 33455820 — intervention group
Group type: EXPERIMENTAL
Intervention: COOK Zenith p‐Branch OTS device
Number of subjects: 23
Study 33067298 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus an enhanced rehabilitation programme (patient-held information workbook, goal setting diary, up to six additional therapy sessions)
Number of subjects: 0
Study 33067298 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study 33067298 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus an enhanced rehabilitation programme (intervention)
Number of subjects: 0
Study 34387261 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based participatory research (CBPR)
Number of subjects: 98
Study 34387261 — intervention group
Group type: COMPARATOR
Intervention: Traditional research
Number of subjects: 98
Study 32785589 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin/relebactam 500 mg/500 mg/250 mg
Number of subjects: 537
Study 32785589 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin/tazobactam 4 g/500 mg
Number of subjects: 537
Study 35113923 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient perspectives on factors influencing RCT recruitment
Number of subjects: 36
Study 35113923 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff perspectives on factors influencing RCT recruitment
Number of subjects: 36
Study 35113923 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall recruitment strategies
Number of subjects: 36
Study 33011874 — intervention group
Group type: EXPERIMENTAL
Intervention: COSMED K5 portable metabolic system
Number of subjects: 27
Study 36202335 — intervention group
Group type: EXPERIMENTAL
Intervention: High symptom burden group (n=20, 45.5%)
Number of subjects: 44
Study 36202335 — intervention group
Group type: EXPERIMENTAL
Intervention: Low symptom burden group (n=24, 54.5%)
Number of subjects: 44
Study 33122393 — intervention group
Group type: EXPERIMENTAL
Intervention: MCSFA-HFD (diet enriched with ∼30 g (5E%) saturated MCFAs)
Number of subjects: 17
Study 33122393 — intervention group
Group type: COMPARATOR
Intervention: LCSFA-HFD (high-fat diet enriched with saturated long-chain fatty acids)
Number of subjects: 17
Study 33122393 — intervention group
Group type: EXPERIMENTAL
Intervention: MCSFA-HFD
Number of subjects: 17
Study 35339715 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid-based regimen (including levofloxacin, pyrazinamide, thioisonicotinamide, amikacin sulfate, sodium p-amino salicylate)
Number of subjects: 50
Study 35339715 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid-based regimen
Number of subjects: 50
Study 35339715 — intervention group
Group type: COMPARATOR
Intervention: Control group (without linezolid)
Number of subjects: 50
Study 33843789 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous estrogen (25 mg)
Number of subjects: 40
Study 33843789 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 40
Study 33246506 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher maternal education
Number of subjects: 3578
Study 33246506 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth interval of at least 2 years
Number of subjects: 3578
Study 33246506 — intervention group
Group type: EXPERIMENTAL
Intervention: Intended conception of the child
Number of subjects: 3578
Study 33246506 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal exposure to physical violence
Number of subjects: 3578
Study 33246506 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of child (18-23 months)
Number of subjects: 3578
Study 33246506 — intervention group
Group type: EXPERIMENTAL
Intervention: Male child
Number of subjects: 3578
Study 36356632 — intervention group
Group type: EXPERIMENTAL
Intervention: aprocitentan 12·5 mg
Number of subjects: 730
Study 36356632 — intervention group
Group type: EXPERIMENTAL
Intervention: aprocitentan 25 mg
Number of subjects: 730
Study 36356632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 730
Study 33470031 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1 GBq radioiodine therapy
Number of subjects: 474
Study 33470031 — intervention group
Group type: COMPARATOR
Intervention: 3.7 GBq radioiodine therapy
Number of subjects: 474
Study 33470031 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 474
Study 32384056 — intervention group
Group type: EXPERIMENTAL
Intervention: Horyzons, a long-term social media-based mental health intervention
Number of subjects: 12
Study 32384056 — intervention group
Group type: EXPERIMENTAL
Intervention: Horyzons
Number of subjects: 12
Study 35927733 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly saline (0.9%) washout in addition to standard LTC care
Number of subjects: 0
Study 35927733 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly citric acid (3.23%) washout in addition to standard LTC care
Number of subjects: 0
Study 35927733 — intervention group
Group type: COMPARATOR
Intervention: Standard LTC care only
Number of subjects: 0
Study 33883252 — intervention group
Group type: EXPERIMENTAL
Intervention: Vadadustat
Number of subjects: 304
Study 35671941 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 38
Study 35671941 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined General Anesthesia with Thoracic Epidural (GA + TEA)
Number of subjects: 38
Study 34881696 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Number of subjects: 5769
Study 34881696 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor plus aspirin
Number of subjects: 5769
Study 32053841 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (50 mg/d)
Number of subjects: 99
Study 32053841 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg/d)
Number of subjects: 99
Study 32053841 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/d)
Number of subjects: 99
Study 34806783 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 300 mg monthly for 12 weeks
Number of subjects: 233
Study 34806783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study 33704680 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hypoparathyroidism
Number of subjects: 48582
Study 33704680 — intervention group
Group type: COMPARATOR
Intervention: Control group (without hypoparathyroidism)
Number of subjects: 48582
Study 33704680 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hypoparathyroidism with kidney imaging
Number of subjects: 48582
Study 33704680 — intervention group
Group type: COMPARATOR
Intervention: Control group with kidney imaging
Number of subjects: 48582
Study 33035274 — intervention group
Group type: EXPERIMENTAL
Intervention: GeneXpert HIV‐1 Qual
Number of subjects: 626
Study 33035274 — intervention group
Group type: EXPERIMENTAL
Intervention: Alere m‐PIMA
Number of subjects: 626
Study 33035274 — intervention group
Group type: EXPERIMENTAL
Intervention: At birth POC testing
Number of subjects: 626
Study 33035274 — intervention group
Group type: EXPERIMENTAL
Intervention: At birth and 6-week POC testing
Number of subjects: 626
Study 35171234 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary metastasectomy (PM)
Number of subjects: 62
Study 32894809 — intervention group
Group type: EXPERIMENTAL
Intervention: High triglyceride group
Number of subjects: 898
Study 32894809 — intervention group
Group type: EXPERIMENTAL
Intervention: Low high-density lipoprotein group
Number of subjects: 898
Study 32894809 — intervention group
Group type: EXPERIMENTAL
Intervention: High low-density lipoprotein group
Number of subjects: 898
Study 32894809 — intervention group
Group type: EXPERIMENTAL
Intervention: High triglyceride group in non-obese men
Number of subjects: 898
Study 32894809 — intervention group
Group type: EXPERIMENTAL
Intervention: High triglyceride group in obese women
Number of subjects: 898
Study 32894809 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertriglyceridemia
Number of subjects: 898
Study 36367721 — intervention group
Group type: EXPERIMENTAL
Intervention: True Acupuncture (TA)
Number of subjects: 226
Study 36367721 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture (SA)
Number of subjects: 226
Study 36367721 — intervention group
Group type: COMPARATOR
Intervention: Waiting List Control (WC)
Number of subjects: 226
Study 34022949 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational interviewing via interactive instant-messaging
Number of subjects: 0
Study 34022949 — intervention group
Group type: COMPARATOR
Intervention: General health text-messages (comparator)
Number of subjects: 0
Study 36056379 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on the ISD model
Number of subjects: 150
Study 36056379 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 150
Study 33506399 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIKES framework educational intervention (30-min didactic + refresher email)
Number of subjects: 124
Study 33506399 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 124
Study 36145083 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine and leucine supplementation (ALs group, n = 20)
Number of subjects: 79
Study 36145083 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised adapted physical activity program (APA group, n = 20)
Number of subjects: 79
Study 36145083 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of arginine and leucine supplementation and supervised adapted physical activity program (ALs+APA group, n = 20)
Number of subjects: 79
Study 36145083 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 19)
Number of subjects: 79
Study 33245150 — intervention group
Group type: EXPERIMENTAL
Intervention: Time Out consultation (TOC) with the general practitioner (GP)
Number of subjects: 154
Study 33245150 — intervention group
Group type: EXPERIMENTAL
Intervention: Time Out consultation (TOC) before treatment decision
Number of subjects: 154
Study 33245150 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TOC)
Number of subjects: 154
Study 35857296 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 17160
Study 33946984 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-stand desks intervention
Number of subjects: 176
Study 33946984 — intervention group
Group type: COMPARATOR
Intervention: Standard desks (Control)
Number of subjects: 176
Study 32144927 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral needling therapy
Number of subjects: 62
Study 32144927 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture treatment
Number of subjects: 62
Study 35063278 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg daily) and Letrozole (2.5 mg daily)
Number of subjects: 74
Study 35063278 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (200 mg daily alternating weeks) and Tamoxifen (20 mg twice daily)
Number of subjects: 74
Study 35069071 — intervention group
Group type: EXPERIMENTAL
Intervention: Kegel exercises regimen (8 weeks, high-intensity, home-based)
Number of subjects: 0
Study 35069071 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal magnetic stimulation (EMS) (2 sessions per week for 8 weeks)
Number of subjects: 0
Study 34540784 — intervention group
Group type: EXPERIMENTAL
Intervention: Information-based health education and continuity of care intervention
Number of subjects: 116
Study 34540784 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 116
Study 33358124 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI + Durvalumab
Number of subjects: 0
Study 33358124 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI + Durvalumab and Tremelimumab
Number of subjects: 0
Study 32112360 — intervention group
Group type: EXPERIMENTAL
Intervention: LAI aripiprazole
Number of subjects: 0
Study 32112360 — intervention group
Group type: COMPARATOR
Intervention: LAI paliperidone
Number of subjects: 0
Study 36241853 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg CBD
Number of subjects: 61
Study 36241853 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg CBD
Number of subjects: 61
Study 36241853 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg CBD
Number of subjects: 61
Study 36241853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 34338408 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin 400 mg
Number of subjects: 277
Study 34338408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study 34338408 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin 200 mg
Number of subjects: 277
Study 32157294 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice grade steaks on day 9
Number of subjects: 21
Study 32157294 — intervention group
Group type: EXPERIMENTAL
Intervention: Select grade steaks on day 9
Number of subjects: 21
Study 32157294 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal location steaks
Number of subjects: 21
Study 32157294 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle location steaks
Number of subjects: 21
Study 32157294 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal location steaks
Number of subjects: 21
Study 32157294 — intervention group
Group type: EXPERIMENTAL
Intervention: All steaks analyzed for metmyoglobin reducing ability (MRA) and oxygen consumption (OC)
Number of subjects: 21
Study 32157294 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I, IIA, and IIX fibers
Number of subjects: 21
Study 34544526 — intervention group
Group type: EXPERIMENTAL
Intervention: CCRT plus Endostar (CCRT+E arm)
Number of subjects: 116
Study 34544526 — intervention group
Group type: COMPARATOR
Intervention: CCRT alone (CCRT arm)
Number of subjects: 116
Study 34544526 — intervention group
Group type: EXPERIMENTAL
Intervention: CCRT plus Endostar (CCRT+E arm) with positive VEGFR2 expression
Number of subjects: 116
Study 34544526 — intervention group
Group type: COMPARATOR
Intervention: CCRT alone (CCRT arm) with positive VEGFR2 expression
Number of subjects: 116
Study 32384462 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable oxygen concentrator with an auto‐DODS
Number of subjects: 20
Study 32384462 — intervention group
Group type: COMPARATOR
Intervention: Continuous‐flow oxygen concentrator
Number of subjects: 20
Study 34971651 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Integrated Care (FICare)
Number of subjects: 126
Study 32150750 — intervention group
Group type: EXPERIMENTAL
Intervention: A-FLU-v (adjuvanted)
Number of subjects: 175
Study 32150750 — intervention group
Group type: COMPARATOR
Intervention: NA-FLU-v (nonadjuvanted)
Number of subjects: 175
Study 34400570 — intervention group
Group type: EXPERIMENTAL
Intervention: Health warning label theme: harming family or children with secondhand smoke
Number of subjects: 3247
Study 34400570 — intervention group
Group type: EXPERIMENTAL
Intervention: Health warning label theme: self-harm from using cigarettes
Number of subjects: 3247
Study 34400570 — intervention group
Group type: EXPERIMENTAL
Intervention: Health warning label theme: reinforcing compliance with existing smoke-free policies
Number of subjects: 3247
Study 34400570 — intervention group
Group type: EXPERIMENTAL
Intervention: Health warning label theme: anticigarette gift giving practices
Number of subjects: 3247
Study 33895882 — intervention group
Group type: EXPERIMENTAL
Intervention: Conbercept
Number of subjects: 160
Study 33895882 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 160
Study 33895882 — intervention group
Group type: EXPERIMENTAL
Intervention: Conbercept and Ranibizumab
Number of subjects: 160